CORDIS · 101004462 · H2020
ATTRACT2 Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2
Coordinator: ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE (CH)
The ATTRACT Phase-2 project aims to consolidate a European innovation ecosystem focused on breakthrough Detection & Imaging technologies. This ecosystem is backboned by three types of actors: National and European RIs, Industrial organizations and their associated communities. Although these actors understand and practice innovation under different rationales, the goal of ATTRACT Phase-2 merges their common aim for overcoming the innovation “Valley-of-Death”. Departing from the success of the ongoing project ATTRACT Phase-1, this project will focus and fund the proven and most promising break…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €35.0M awarded to the consortium. The project runs over approximately 4.5 years from 2021-02-01 to 2025-07-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- STEMBANCC — Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)115439 · FP7 · €26.0M
- IABC PROGRAMME — iABC Programme115721 · FP7 · €24.3M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
- EU-AIMS — European Autism Interventions - A Multicentre Study for Developing New Medications115300 · FP7 · €20.5M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €35.0M toward a total project budget of €35.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-INFRAINNOV-2019-2020.
- Who coordinates the project?
- The project is coordinated by ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE (CH).
- What is the project timeline?
- The project runs from 2021-02-01 to 2025-07-31 — approximately 4.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101004462.